Lipocine
LPCN
32 hedge funds and large institutions have $2.12M invested in Lipocine in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
7% more funds holding
Funds holding: 30 → 32 (+2)
0.15% more ownership
Funds ownership: 0.75% → 0.9% (+0.15%)
76% less capital invested
Capital invested by funds: $8.88M → $2.12M (-$6.76M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$1.95M |
| 2 |
BlackRock
New York
|
+$604K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$554K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$410K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$312K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $1K | – | – | – |
|
27
Morgan Stanley
New York
| $1K | – | – | – |
|
28
Dimensional Fund Advisors
Austin,
Texas
| – | -$404K | -8,451 | Closed |
|
|
KCM
29
Knoll Capital Management
Miami,
Florida
| – | -$141K | -2,941 | Closed |
|
|
QCMA
30
Quad Capital Management Advisors
New York
| – | -$124K | -2,588 | Closed |
|
31
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$111K | -2,328 | Closed |
|
|
FIA
32
FNY Investment Advisers
New York
| – | -$40.1K | -1,567 | Closed |
|
33
Bank of America
Charlotte,
North Carolina
| – | -$435 | -17 | -22% |
|
34
Barclays
London,
United Kingdom
| – | -$77 | -3 | Closed |
|
35
BNP Paribas Financial Markets
Paris,
France
| – | -$11 | – | – |
|
|
MF
36
Manchester Financial
Westlake Village,
California
| – | +$743 | +29 | New |
|
37
Simplex Trading
Chicago,
Illinois
| – | +$1.2K | +47 | New |
|
LPCN Hedge Fund Activity: Q4 2019 in Review
32 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2019, worth a combined $2.12M — down 76% from $8.88M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LPCN positions and 7 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.95M. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $404K sold.
- 32 institutional investors held Lipocine (LPCN) as of Q4 2019, up from 30 in Q3 2019.
- Funds reported $2.12M of Lipocine stock for Q4 2019, down 76% quarter-over-quarter.
- 9 funds opened new Lipocine positions in Q4 2019 and 7 closed out, a net change of +2 holders.
- The largest Lipocine buyer in Q4 2019 was Renaissance Technologies, an estimated $1.95M added.
- The largest Lipocine seller in Q4 2019 was Dimensional Fund Advisors, an estimated $404K sold.
Based on aggregated 13F filings for Q4 2019.